Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000036.xml
Download PDF
Laryngorhinootologie 2020; 99(09): 637-640
DOI: 10.1055/a-1153-9088
DOI: 10.1055/a-1153-9088
Der interessante Fall
Unklare persistierende Dysphonie bei Patientin mit hämatoonkologischer Grunderkrankung
Unclear persistent dysphonia in patient with underlying hemato-oncological diseaseAuthors
Fallbericht
Eine 87-jährige Patientin stellte sich in unserer HNO-Ambulanz zur Abklärung einer seit 6 Monaten bestehenden intermittierenden und aktuell persistierenden Heiserkeit vor. Die Patientin war bis auf die Dysphonie in einem guten Allgemein- und schlanken Ernährungszustand. Sie war lebensfroh, Rollator-mobil, lebte allein und wurde durch eine Haushaltshilfe unterstützt (ECOG 2).
Publication History
Received: 25 March 2020
Accepted: 03 April 2020
Article published online:
22 April 2020
© Georg Thieme Verlag KG
Stuttgart · New York
-
Literatur
- 1 Allegra E, Marino N, Modica D. et al. Primary laryngeal localization of multiple myeloma: A case report. Mol Clin Oncol 2017; 6: 154-156
- 2 Bjelkenkrantz K, Lundgren J, Olofsson J. Extramedullary plasmacytoma of the larynx. J Otolaryngol 1981; 10: 28-34
- 3 Flore B, Hermans R. Multiple myeloma involving the cricoid cartilage. JBR-BTR 2013; 96: 87-88
- 4 Ge S, Zhu G, Yi Y. Extramedullary plasmacytoma of the larynx: Literature review and report of a case who subsequently developed acute myeloid leukemia. Oncol Lett 2018; 16: 2995-3004
- 5 Grobman AB. et al Laryngeal involvement of multiple myeloma. Case reports in oncological medicine 2012; 2012: 257-814
- 6 Jizzini MN, Shah M, Yeung SJ. Extramedullary Plasmacytoma Involving the Trachea: A Case Report and Literature Review. J Emerg Med 2019; 57: e65-e67
- 7 Kaanders JHAM, Werner JA, Wendt TG. et al. Larynxkarzinom. In: Schmoll HJ, Höffken K, Possinger K. eds Kompendium Internistische Onkologie: Standards in Diagnostik und Therapie. Berlin, Heidelberg: Springer Berlin Heidelberg; 2006: 3397-3420
- 8 Kumar SK, Callander NS, Hillengass J. et al. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. J Natl Compr Canc Netw 2019; 17: 1154-1165
- 9 Lamb YN. Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma. Drugs 2018; 78: 1481-1488
- 10 Mitchell HK. et al. Extramedullary relapse of multiple myeloma in the thyroid cartilage. Case Reports 2013; 2013: bcr2013200689
- 11 Moreau P, San Miguel J, Sonneveld P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv52-iv61
- 12 Nochikattil SK, Iype EM, Ramrao SK. et al. A Case of Multiple Myeloma: Mimicking Carcinoma Larynx. Indian J Otolaryngol Head Neck Surg 2016; 68: 534-536
- 13 Soutar R, Lucraft H, Jackson G. et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Clin Oncol (R Coll Radiol) 2004; 16: 405-413
- 14 Steinke KV, Schneider BK, Welkoborsky HJ. Rare Differential Diagnosis of Dyspnea: Extramedullary Plasmocytoma (EMP) of the Larynx-Case Report and Review of the Latest Literature of Laryngeal EMP and Laryngeal Involvement of Multiple Myeloma. Case Rep Otolaryngol 2019; 5654014
- 15 Trudel S, Moreau P, Touzeau C. Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective. Onco Targets Ther 2019; 12: 5813-5822